| Autor: |
Jafari, Alexander J., Owens, Kyle S., Yang, Shengping, Chen, Lauren H., Jolin, Katherine A., Murina, Andrea T., Boh, Erin E. |
| Předmět: |
|
| Zdroj: |
International Journal of Dermatology; Jun2023, Vol. 62 Issue 6, pe333-e335, 3p |
| Abstrakt: |
A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the medical board of the national psoriasis foundation. A United States psoriasis registry reported 55 HZ events in 10,469 patients.[5] Current HZ immunization guidelines for the zoster vaccine include all immunocompetent patients 50 years or older. Lifetime incidence of herpes zoster (HZ) in the U.S is 10-20%.[1] Age and immunosuppression are risk factors for HZ due to the waning of cell-mediated immunity.[2] Autoimmune conditions such as systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease are associated with an increased risk of HZ, which can be further altered by the use of systemic therapies.[[3]] There are conflicting data on the risk of HZ infection in patients with psoriasis in relation to systemic or biologic treatment status. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text